Clinical Respiratory Journal最新文献_第9页

The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma Siglec-15在肺腺癌中的表达特征和预后作用

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-09 DOI: 10.1111/crj.13772

Haijun Sun, Qilong Du, Yuyu Xu, Cheng Rao, Li Xu, Junrong Yang, Yuan Mao, Lin Wang

Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) has been identified as an immune suppressor and a promising candidate for immunotherapy of cancer management. However, the association between Siglec-15 expression and clinicopathological features of lung adenocarcinoma (LUAD), especially the prognostic role, is not fully elucidated. In this present study, a serial of bioinformatics analyses in both tissue and cell levels were conducted to provide an overview of Siglec-15 expression. Real-time quantitative PCR (qPCR) test, western blotting assay, and immunohistochemistry (IHC) analyses were conducted to evaluate the expression of Siglec-15 in LUAD. Survival analysis and Kaplan–Meier curve were employed to describe the prognostic parameters of LUAD. The results of bioinformatics analyses demonstrated the up-regulation of Siglec-15 expression in LUAD. The data of qPCR, western blotting, and IHC analyses further proved that the expression of Siglec-15 in LUAD tissues was significantly increased than that in noncancerous tissues. Moreover, the expression level of Siglec-15 protein in LUAD was substantially associated with TNM stage. LUAD cases with up-regulated Siglec-15 expression, positive N status, and advance TNM stage suffered a critical unfavorable prognosis. In conclusion, Siglec-15 could be identified as a novel prognostic biomarker in LUAD and targeting Siglec-15 may provide a promising strategy for LUAD immunotherapy.

已发现Sialic酸结合免疫球蛋白样凝集素-15（Siglec-15）是一种免疫抑制因子，也是一种有希望用于癌症免疫疗法的候选物质。然而，Siglec-15 的表达与肺腺癌（LUAD）的临床病理特征，尤其是预后作用之间的关联尚未完全阐明。本研究在组织和细胞水平上进行了一系列生物信息学分析，以提供 Siglec-15 表达的概况。本研究通过实时定量 PCR（qPCR）检测、Western 印迹检测和免疫组织化学（IHC）分析来评估 Siglec-15 在 LUAD 中的表达。研究采用生存分析和 Kaplan-Meier 曲线来描述 LUAD 的预后参数。生物信息学分析结果表明，Siglec-15在LUAD中表达上调。qPCR、Western印迹和IHC分析数据进一步证明，Siglec-15在LUAD组织中的表达明显高于非癌组织。此外，Siglec-15蛋白在LUAD中的表达水平与TNM分期密切相关。Siglec-15表达上调、N状态阳性和TNM分期提前的LUAD病例预后极差。总之，Siglec-15可被确定为LUAD的一种新型预后生物标志物，靶向Siglec-15可为LUAD的免疫治疗提供一种前景广阔的策略。

{"title":"The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma","authors":"Haijun Sun, Qilong Du, Yuyu Xu, Cheng Rao, Li Xu, Junrong Yang, Yuan Mao, Lin Wang","doi":"10.1111/crj.13772","DOIUrl":"10.1111/crj.13772","url":null,"abstract":"<p>Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) has been identified as an immune suppressor and a promising candidate for immunotherapy of cancer management. However, the association between Siglec-15 expression and clinicopathological features of lung adenocarcinoma (LUAD), especially the prognostic role, is not fully elucidated. In this present study, a serial of bioinformatics analyses in both tissue and cell levels were conducted to provide an overview of Siglec-15 expression. Real-time quantitative PCR (qPCR) test, western blotting assay, and immunohistochemistry (IHC) analyses were conducted to evaluate the expression of Siglec-15 in LUAD. Survival analysis and Kaplan–Meier curve were employed to describe the prognostic parameters of LUAD. The results of bioinformatics analyses demonstrated the up-regulation of Siglec-15 expression in LUAD. The data of qPCR, western blotting, and IHC analyses further proved that the expression of Siglec-15 in LUAD tissues was significantly increased than that in noncancerous tissues. Moreover, the expression level of Siglec-15 protein in LUAD was substantially associated with TNM stage. LUAD cases with up-regulated Siglec-15 expression, positive N status, and advance TNM stage suffered a critical unfavorable prognosis. In conclusion, Siglec-15 could be identified as a novel prognostic biomarker in LUAD and targeting Siglec-15 may provide a promising strategy for LUAD immunotherapy.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13772","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful bilateral lung transplantation in pulmonary alveolar microlithiasis: A case report and review of literature 肺泡微石症患者成功进行了双侧肺移植：病例报告和文献综述。

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-09 DOI: 10.1111/crj.13773

Parviz Mardani, Reyhaneh Naseri, Reza Shahriarirad, Hadiseh Mahram, Masoud Shafi, Tahmoores Niknam, Mohammad Bagher Khosravi, Mohammad Javad Fallahi, Armin Amirian

Background

Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive genetic disorder with approximately 1000 known cases worldwide, in which calcium phosphate microliths deposit in the alveolar air spaces. As of writing this report, no definitive conventional therapy exists, and many PAM cases may progress to severe respiratory failure and potential death. Bilateral lung transplantation (BLx) seems to be the most optimal solution; however, this procedure is challenging along with limited reports regarding the outcome in PAM. We report a case of PAM successfully treated with BLx for the first time in Iran.

Method

We present the case of a 42-year-old female with a longstanding history of cough, not responding to conventional antitussive medication, who was diagnosed as a case of PAM following a hospitalization due to coughing, dyspnea on exertion, and hemoptysis. Despite treatment with corticosteroid and medical treatment, no improvement was achieved and she subsequently developed respiratory and right ventricular failure, with oxygen ventilation dependence. Eventually, she was scheduled for BLx. The operation was successful and during her 2-year follow-up, no recurrence or significant postoperative complications has been reported.

Conclusion

This case presentation and literature review confirm the effectiveness of BLx as a promising treatment for PAM-diagnosed patients, improving both life expectancy and quality of life.

背景：肺泡微结石症（PAM）是一种罕见的常染色体隐性遗传疾病，全世界已知约有 1000 例，患者的肺泡气隙中会沉积磷酸钙微结石。截至撰写本报告时，尚无明确的常规疗法，许多 PAM 病例可能会发展为严重的呼吸衰竭，甚至死亡。双侧肺移植（BLx）似乎是最理想的解决方案；然而，这种手术具有挑战性，而且有关 PAM 结果的报道也很有限。我们首次在伊朗报告了一例通过 BLx 成功治疗 PAM 的病例：我们报告了一例 42 岁女性的病例，她有长期咳嗽史，对常规止咳药无反应，因咳嗽、用力时呼吸困难和咯血住院后被诊断为 PAM。尽管她接受了皮质类固醇治疗和药物治疗，但病情仍不见好转，随后出现呼吸衰竭和右心室衰竭，并依赖氧气通气。最终，她被安排接受 BLx 手术。手术很成功，在两年的随访中，没有发现复发或明显的术后并发症：本病例和文献综述证实，BLx 是治疗 PAM 诊断患者的有效方法，可改善患者的预期寿命和生活质量。

{"title":"Successful bilateral lung transplantation in pulmonary alveolar microlithiasis: A case report and review of literature","authors":"Parviz Mardani, Reyhaneh Naseri, Reza Shahriarirad, Hadiseh Mahram, Masoud Shafi, Tahmoores Niknam, Mohammad Bagher Khosravi, Mohammad Javad Fallahi, Armin Amirian","doi":"10.1111/crj.13773","DOIUrl":"10.1111/crj.13773","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive genetic disorder with approximately 1000 known cases worldwide, in which calcium phosphate microliths deposit in the alveolar air spaces. As of writing this report, no definitive conventional therapy exists, and many PAM cases may progress to severe respiratory failure and potential death. Bilateral lung transplantation (BLx) seems to be the most optimal solution; however, this procedure is challenging along with limited reports regarding the outcome in PAM. We report a case of PAM successfully treated with BLx for the first time in Iran.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>We present the case of a 42-year-old female with a longstanding history of cough, not responding to conventional antitussive medication, who was diagnosed as a case of PAM following a hospitalization due to coughing, dyspnea on exertion, and hemoptysis. Despite treatment with corticosteroid and medical treatment, no improvement was achieved and she subsequently developed respiratory and right ventricular failure, with oxygen ventilation dependence. Eventually, she was scheduled for BLx. The operation was successful and during her 2-year follow-up, no recurrence or significant postoperative complications has been reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case presentation and literature review confirm the effectiveness of BLx as a promising treatment for PAM-diagnosed patients, improving both life expectancy and quality of life.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13773","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk and prognosis of secondary lung cancer after radiation therapy for thoracic malignancies 胸部恶性肿瘤放疗后继发肺癌的风险和预后。

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-09 DOI: 10.1111/crj.13760

Kang Chen, Chong Liu, Xueman Li, Tianyou Chen, Shan Liu, Fei Xiong, Zhou Zhang

Objective

Radiation therapy (RT) may increase the risk of second cancer. This study aimed to determine the association between exposure to radiotherapy for the treatment of thoracic cancer (TC) and subsequent secondary lung cancer (SLC).

Materials and Methods

The Surveillance, Epidemiology, and End Results (SEER) database (from 1975 to 2015) was queried for TC. Univariate Cox regression analyses and multiple primary standardized incidence ratios (SIRs) were used to assess the risk of SLC. Subgroup analyses of patients stratified by latency time since TC diagnosis, age at TC diagnosis, and calendar year of TC diagnosis stage were also performed. Overall survival and SLC-related death were compared among the RT and no radiation therapy (NRT) groups by using Kaplan–Meier analysis and competitive risk analysis.

Results

In a total of 329 129 observations, 147 847 of whom had been treated with RT. And 6799 patients developed SLC. Receiving radiotherapy was related to a higher risk of developing SLC for TC patients (adjusted HR, 1.25; 95% CI, 1.19–1.32; P < 0.001). The cumulative incidence of developing SLC in TC patients with RT (3.8%) was higher than the cumulative incidence (2.9%) in TC patients with NRT(P). The incidence risk of SLC in TC patients who received radiotherapy was significantly higher than the US general population (SIR, 1.19; 95% CI, 1.14–1.23; P < 0.050).

Conclusions

Radiotherapy for TC was associated with higher risks of developing SLC compared with patients unexposed to radiotherapy.

目的：放射治疗（RT）可能会增加罹患第二种癌症的风险。本研究旨在确定为治疗胸腺癌（TC）而接受放射治疗与随后的继发性肺癌（SLC）之间的关系：对监测、流行病学和最终结果（SEER）数据库（1975 年至 2015 年）中的 TC 进行了查询。采用单变量 Cox 回归分析和多重一级标准化发病率比 (SIR) 评估 SLC 风险。此外，还按 TC 诊断后的潜伏时间、TC 诊断时的年龄和 TC 诊断阶段的日历年对患者进行了分组分析。通过卡普兰-梅耶分析和竞争风险分析，比较了放疗组和未放疗组的总生存率和SLC相关死亡：结果：在329 129名观察对象中，有147 847人接受了RT治疗。6799 名患者出现了 SLC。接受放疗与 TC 患者罹患 SLC 的较高风险有关（调整后 HR，1.25；95% CI，1.19-1.32；P 结论：TC 患者接受放疗与罹患 SLC 的较高风险有关（调整后 HR，1.25；95% CI，1.19-1.32；P）：与未接受放疗的患者相比，TC 患者接受放疗后患 SLC 的风险更高。

{"title":"Risk and prognosis of secondary lung cancer after radiation therapy for thoracic malignancies","authors":"Kang Chen, Chong Liu, Xueman Li, Tianyou Chen, Shan Liu, Fei Xiong, Zhou Zhang","doi":"10.1111/crj.13760","DOIUrl":"10.1111/crj.13760","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Radiation therapy (RT) may increase the risk of second cancer. This study aimed to determine the association between exposure to radiotherapy for the treatment of thoracic cancer (TC) and subsequent secondary lung cancer (SLC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>The Surveillance, Epidemiology, and End Results (SEER) database (from 1975 to 2015) was queried for TC. Univariate Cox regression analyses and multiple primary standardized incidence ratios (SIRs) were used to assess the risk of SLC. Subgroup analyses of patients stratified by latency time since TC diagnosis, age at TC diagnosis, and calendar year of TC diagnosis stage were also performed. Overall survival and SLC-related death were compared among the RT and no radiation therapy (NRT) groups by using Kaplan–Meier analysis and competitive risk analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In a total of 329 129 observations, 147 847 of whom had been treated with RT. And 6799 patients developed SLC. Receiving radiotherapy was related to a higher risk of developing SLC for TC patients (adjusted HR, 1.25; 95% CI, 1.19–1.32; <i>P</i> < 0.001). The cumulative incidence of developing SLC in TC patients with RT (3.8%) was higher than the cumulative incidence (2.9%) in TC patients with NRT(P). The incidence risk of SLC in TC patients who received radiotherapy was significantly higher than the US general population (SIR, 1.19; 95% CI, 1.14–1.23; <i>P</i> < 0.050).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Radiotherapy for TC was associated with higher risks of developing SLC compared with patients unexposed to radiotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13760","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An 18F-FDG-PET/CT-based radiomics signature for estimating malignance probability of solitary pulmonary nodule 基于18F-FDG-PET/CT的放射组学特征，用于估计单发肺结节的恶性概率。

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-09 DOI: 10.1111/crj.13751

Jingchi Zheng, Yue Hao, Yan Guo, Ming Du, Pengyuan Wang, Jun Xin

Background

Some solitary pulmonary nodules (SPNs) as early manifestations of lung cancer, it is difficult to determine its nature, which brings great trouble to clinical diagnosis and treatment. Radiomics can deeply explore the essence of images and provide clinical decision support for clinicians. The purpose of our study was to explore the effect of positron emission tomography (PET) with 2-deoxy-2-[fluorine-18] fluoro-d-glucose integrated with computed tomography (CT; ¹⁸F-FDG-PET/CT) combined with radiomics for predicting probability of malignancy of SPNs.

Methods

We retrospectively enrolled 190 patients with SPNs confirmed by pathology from January 2013 to December 2019 in our hospital. SPNs were benign in 69 patients and malignant in 121 patients. Patients were randomly divided into a training or testing group at a ratio of 7:3. Three-dimensional regions of interest (ROIs) were manually outlined on PET and CT images, and radiomics features were extracted. Synthetic minority oversampling technique (SMOTE) method was used to balance benign and malignant samples to a ratio of 1:1. In the training group, least absolute shrinkage and selection operator (LASSO) regression analyses and Spearman correlation analyses were used to select the strongest radiomics features. Three models including PET model, CT model, and joint model were constructed using multivariate logistic regression analysis. Receiver operating characteristic (ROC) curves, calibration curves, and decision curves were plotted to evaluate diagnostic efficiency, calibration degree, and clinical usefulness of all models in training and testing groups.

Results

The estimative effectiveness of the joint model was superior to the CT or PET model alone in the training and testing groups. For the joint model, CT model, and PET model, area under the ROC curve was 0.929, 0.819, 0.833 in the training group, and 0.844, 0.759, 0.748 in the testing group, respectively. Calibration and decision curves showed good fit and clinical usefulness for the joint model in both training and testing groups.

Conclusion

Radiomics models constructed by combining PET and CT radiomics features are valuable for distinguishing benign and malignant SPNs. The combined effect is superior to qualitative diagnoses with CT or PET radiomics models alone.

背景：一些单发性肺部结节（SPN）作为肺癌的早期表现，难以确定其性质，给临床诊断和治疗带来了极大的困扰。放射组学可以深入挖掘图像的本质，为临床医生提供临床决策支持。我们的研究旨在探讨 2-脱氧-2-[氟-18] 氟-d-葡萄糖正电子发射断层扫描（PET）与计算机断层扫描（CT；18F-FDG-PET/CT）结合放射组学预测 SPN 恶性概率的效果：我们回顾性地纳入了我院2013年1月至2019年12月期间经病理证实的190例SPN患者。69例患者的SPN为良性，121例患者的SPN为恶性。患者按7:3的比例随机分为训练组和测试组。在 PET 和 CT 图像上手动勾勒出三维感兴趣区（ROI），并提取放射组学特征。使用合成少数过采样技术（SMOTE）方法将良性样本和恶性样本的比例平衡为 1:1。在训练组中，使用最小绝对收缩和选择算子（LASSO）回归分析和斯皮尔曼相关分析来选择最强的放射组学特征。利用多变量逻辑回归分析构建了三个模型，包括 PET 模型、CT 模型和联合模型。绘制了接收者操作特征曲线（ROC）、校准曲线和决策曲线，以评估所有模型在训练组和测试组的诊断效率、校准程度和临床实用性：结果：在培训组和测试组中，联合模型的估计效果优于单独的 CT 或 PET 模型。联合模型、CT 模型和 PET 模型的 ROC 曲线下面积在培训组分别为 0.929、0.819 和 0.833，在测试组分别为 0.844、0.759 和 0.748。校准和决策曲线显示，联合模型在训练组和测试组都具有良好的拟合度和临床实用性：结论：结合PET和CT放射组学特征构建的放射组学模型对区分良性和恶性SPN很有价值。结论：结合 PET 和 PET 放射线组学特征构建的放射线组学模型对区分良性和恶性 SPN 很有价值，其综合效果优于单独使用 CT 或 PET 放射线组学模型进行定性诊断。

{"title":"An 18F-FDG-PET/CT-based radiomics signature for estimating malignance probability of solitary pulmonary nodule","authors":"Jingchi Zheng, Yue Hao, Yan Guo, Ming Du, Pengyuan Wang, Jun Xin","doi":"10.1111/crj.13751","DOIUrl":"10.1111/crj.13751","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Some solitary pulmonary nodules (SPNs) as early manifestations of lung cancer, it is difficult to determine its nature, which brings great trouble to clinical diagnosis and treatment. Radiomics can deeply explore the essence of images and provide clinical decision support for clinicians. The purpose of our study was to explore the effect of positron emission tomography (PET) with 2-deoxy-2-[fluorine-18] fluoro-<span>d</span>-glucose integrated with computed tomography (CT; <sup>18</sup>F-FDG-PET/CT) combined with radiomics for predicting probability of malignancy of SPNs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively enrolled 190 patients with SPNs confirmed by pathology from January 2013 to December 2019 in our hospital. SPNs were benign in 69 patients and malignant in 121 patients. Patients were randomly divided into a training or testing group at a ratio of 7:3. Three-dimensional regions of interest (ROIs) were manually outlined on PET and CT images, and radiomics features were extracted. Synthetic minority oversampling technique (SMOTE) method was used to balance benign and malignant samples to a ratio of 1:1. In the training group, least absolute shrinkage and selection operator (LASSO) regression analyses and Spearman correlation analyses were used to select the strongest radiomics features. Three models including PET model, CT model, and joint model were constructed using multivariate logistic regression analysis. Receiver operating characteristic (ROC) curves, calibration curves, and decision curves were plotted to evaluate diagnostic efficiency, calibration degree, and clinical usefulness of all models in training and testing groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The estimative effectiveness of the joint model was superior to the CT or PET model alone in the training and testing groups. For the joint model, CT model, and PET model, area under the ROC curve was 0.929, 0.819, 0.833 in the training group, and 0.844, 0.759, 0.748 in the testing group, respectively. Calibration and decision curves showed good fit and clinical usefulness for the joint model in both training and testing groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Radiomics models constructed by combining PET and CT radiomics features are valuable for distinguishing benign and malignant SPNs. The combined effect is superior to qualitative diagnoses with CT or PET radiomics models alone.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis 非小细胞肺癌患者新辅助化疗联合手术的疗效：荟萃分析。

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-09 DOI: 10.1111/crj.13756

Hai-jun Dong, Cheng-yan Yang

Introduction

This meta-analysis sought to investigate the effect of neoadjuvant chemotherapy (NACT) combined with surgery in patients with nonsmall cell lung cancer (NSCLC).

Methods

With time span from January 2010 to December 2022, PubMed, Web of Science and Embase, China National Knowledge Infrastructure, and WanFang databases were searched for randomized controlled trials on comparison between NACT combined with surgery and surgery alone in patients with NSCLC. Then a meta-analysis was performed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.

Results

A total of 1511 studies were retrieved and 12 were finally included. Meta-analysis results showed that compared with surgery alone, a combination of NACT and surgery was associated with higher treatment response rate (odds ratio, OR = 2.459, 95% confidence interval, CI [1.785, 3.388], P < 0.001), 1-year survival rate (OR = 2.185, 95% CI [1.608, 2.970], P < 0.001), and 3-year survival rate (OR = 2.195, 95% CI [1.568, 3.073], P < 0.001) and lower levels of intraoperative blood loss (standardized mean difference, SMD = −0.932, 95% CI [−1.588, −0.275], P = 0.005) and length of hospital stay (SMD = −0.481, 95% CI [−0.933, −0.028], P = 0.037).

Conclusion

NACT combined with surgery is superior to surgery alone in the treatment of NSCLC and can promote postoperative recovery. Collectively, such combination is a safe and effective treatment for patients with NSCLC.

简介：这项荟萃分析旨在研究非小细胞肺癌（NSCLC）患者新辅助化疗（NACT）联合手术的效果：该荟萃分析旨在研究新辅助化疗（NACT）联合手术治疗非小细胞肺癌（NSCLC）患者的效果：时间跨度为2010年1月至2022年12月，在PubMed、Web of Science、Embase、中国知网和万方数据库中检索了NACT联合手术与单纯手术治疗NSCLC患者的随机对照试验。然后根据系统综述和荟萃分析首选报告项目（PRISMA）指南进行荟萃分析：结果：共检索到 1511 项研究，最终纳入 12 项。Meta分析结果显示，与单独手术相比，NACT与手术联合治疗的治疗反应率更高（几率比，OR=2.459，95%置信区间，CI [1.785，3.388]，P 结论：NACT与手术联合治疗优于单独手术：在治疗 NSCLC 时，NACT 联合手术优于单独手术，并能促进术后恢复。总之，这种联合疗法对 NSCLC 患者来说是一种安全有效的治疗方法。

{"title":"Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis","authors":"Hai-jun Dong, Cheng-yan Yang","doi":"10.1111/crj.13756","DOIUrl":"10.1111/crj.13756","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>This meta-analysis sought to investigate the effect of neoadjuvant chemotherapy (NACT) combined with surgery in patients with nonsmall cell lung cancer (NSCLC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>With time span from January 2010 to December 2022, PubMed, Web of Science and Embase, China National Knowledge Infrastructure, and WanFang databases were searched for randomized controlled trials on comparison between NACT combined with surgery and surgery alone in patients with NSCLC. Then a meta-analysis was performed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1511 studies were retrieved and 12 were finally included. Meta-analysis results showed that compared with surgery alone, a combination of NACT and surgery was associated with higher treatment response rate (odds ratio, OR = 2.459, 95% confidence interval, CI [1.785, 3.388], <i>P</i> < 0.001), 1-year survival rate (OR = 2.185, 95% CI [1.608, 2.970], <i>P</i> < 0.001), and 3-year survival rate (OR = 2.195, 95% CI [1.568, 3.073], <i>P</i> < 0.001) and lower levels of intraoperative blood loss (standardized mean difference, SMD = −0.932, 95% CI [−1.588, −0.275], <i>P</i> = 0.005) and length of hospital stay (SMD = −0.481, 95% CI [−0.933, −0.028], <i>P</i> = 0.037).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>NACT combined with surgery is superior to surgery alone in the treatment of NSCLC and can promote postoperative recovery. Collectively, such combination is a safe and effective treatment for patients with NSCLC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13756","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Abnormal methylation mediated upregulation of LINC00857 boosts malignant progression of lung adenocarcinoma by modulating the miR-486-5p/NEK2 axis 异常甲基化介导的 LINC00857 上调通过调节 miR-486-5p/NEK2 轴促进肺腺癌的恶性进展

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-09 DOI: 10.1111/crj.13765

Haoyu Fu, Mingming Zhang, Xiaohui Liu, Yiming Yang, Ying Xing

LINC00857 is frequently dysregulated in varying cancers, which in turn exerts carcinogenic effects; however, its DNA methylation status in promoter region and molecular mechanisms underlying the progression of lung adenocarcinoma (LUAD) remain rarely understood. Through bioinformatics analysis, we examined the expression state and methylation site of LINC00857 in LUAD and further investigated the properties of LINC00857 as a competitive endogenous RNA in the cancer progression. The current study revealed that the overexpression of LINC00857 in LUAD tissue and cells was mainly caused by the hypomethylation of the promoter region. LINC00857 knockdown prominently reduced cell proliferation, impeded cell migration and invasion, and restrained lymph node metastasis, with enhancing radiosensitivity. The effects of LINC00857 on tumor growth were also investigated in nude mice models. Subsequently, the downstream factors, miR-486-5p and NEK2, were screened, and the putative regulatory axis was examined. Overall, the regulatory effect of methylation-mediated LINC00857 overexpression on miR-486-5p/NEK2 axis may be a new mechanism for LUAD progression.

LINC00857经常在各种癌症中表达失调，进而产生致癌作用；然而，其在启动子区的DNA甲基化状态以及肺腺癌（LUAD）进展的分子机制仍然鲜为人知。通过生物信息学分析，我们检测了 LINC00857 在 LUAD 中的表达状态和甲基化位点，并进一步研究了 LINC00857 作为竞争性内源性 RNA 在癌症进展中的特性。目前的研究发现，LINC00857在LUAD组织和细胞中的过表达主要是由启动子区的低甲基化引起的。敲除LINC00857能显著降低细胞增殖，阻碍细胞迁移和侵袭，抑制淋巴结转移，并增强放射敏感性。研究人员还在裸鼠模型中考察了 LINC00857 对肿瘤生长的影响。随后，还筛选了下游因子 miR-486-5p 和 NEK2，并研究了推定的调控轴。总之，甲基化介导的LINC00857过表达对miR-486-5p/NEK2轴的调控作用可能是LUAD进展的一种新机制。

{"title":"Abnormal methylation mediated upregulation of LINC00857 boosts malignant progression of lung adenocarcinoma by modulating the miR-486-5p/NEK2 axis","authors":"Haoyu Fu, Mingming Zhang, Xiaohui Liu, Yiming Yang, Ying Xing","doi":"10.1111/crj.13765","DOIUrl":"https://doi.org/10.1111/crj.13765","url":null,"abstract":"<p>LINC00857 is frequently dysregulated in varying cancers, which in turn exerts carcinogenic effects; however, its DNA methylation status in promoter region and molecular mechanisms underlying the progression of lung adenocarcinoma (LUAD) remain rarely understood. Through bioinformatics analysis, we examined the expression state and methylation site of LINC00857 in LUAD and further investigated the properties of LINC00857 as a competitive endogenous RNA in the cancer progression. The current study revealed that the overexpression of LINC00857 in LUAD tissue and cells was mainly caused by the hypomethylation of the promoter region. LINC00857 knockdown prominently reduced cell proliferation, impeded cell migration and invasion, and restrained lymph node metastasis, with enhancing radiosensitivity. The effects of LINC00857 on tumor growth were also investigated in nude mice models. Subsequently, the downstream factors, miR-486-5p and NEK2, were screened, and the putative regulatory axis was examined. Overall, the regulatory effect of methylation-mediated LINC00857 overexpression on miR-486-5p/NEK2 axis may be a new mechanism for LUAD progression.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13765","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140895236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer PD-1/PD-L1抑制剂在老年晚期非小细胞肺癌患者中的疗效和安全性。

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-08 DOI: 10.1111/crj.13763

Li Li, Chunhua Xu, Wei Wang, Qian Zhang

Objective

This study aimed to investigate the efficacy and safety of PD-1/PD-L1 inhibitors in treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).

Methods

Patients with advanced NSCLC ≥70 years old who received PD-1/PD-L1 inhibitors in our hospital were retrospectively analyzed. According to age, the patient were stratified as follows: 70–75 years old, 76–80 years old, and >80 years old. Kaplan–Meier method was used for survival analysis, and univariate and multivariate Cox proportional hazards regression models were used to analyze the correlation between different clinical characteristics and survival.

Results

A total of 58 elderly patients with advanced non-small cell cancer were enrolled in this study. Patients aged 70–75, 76–80, and >80 years old were 32, 19, and 7, respectively. For the all, median OS was 17.0 months, and PFS was 7.0 months. PFS and OS did not differ according to age (P = 0.396, 0.054, respectively). Univariate analysis showed that PS of 0–1, stage III, first-line therapy and irAEs were associated with longer PFS, and PS of 0–1, stage III, and first-line therapy were associated with longer OS. Multivariate analysis showed that patients with stage III had longer PFS. PFS and OS of patients with PS ≥ 2 were significantly shorter than those of patients with PS of 0–1.

Conclusions

In the present real-world retrospective cohort, PD-1/PD-L1 inhibitors are effective and well tolerated in elderly patients with advanced NSCLC. Immunotherapy should be actively used as early as possible in older patients advanced NSCLC.

研究目的本研究旨在探讨PD-1/PD-L1抑制剂治疗老年晚期非小细胞肺癌（NSCLC）患者的有效性和安全性：回顾性分析在我院接受PD-1/PD-L1抑制剂治疗的年龄≥70岁的晚期NSCLC患者。根据年龄对患者进行分层如下：70-75岁、76-80岁和>80岁。采用 Kaplan-Meier 法进行生存率分析，并采用单变量和多变量 Cox 比例危险回归模型分析不同临床特征与生存率之间的相关性：本研究共纳入了 58 名老年晚期非小细胞癌患者。年龄在70-75岁、76-80岁和80岁以上的患者分别有32人、19人和7人。所有患者的中位 OS 为 17.0 个月，PFS 为 7.0 个月。PFS和OS与年龄无关（分别为0.396和0.054）。单变量分析显示，PS为0-1、III期、一线治疗和irAEs与较长的PFS相关，而PS为0-1、III期和一线治疗与较长的OS相关。多变量分析显示，III期患者的PFS更长。PS≥2患者的PFS和OS明显短于PS为0-1的患者：在本真实世界回顾性队列中，PD-1/PD-L1抑制剂对老年晚期NSCLC患者有效且耐受性良好。老年晚期NSCLC患者应尽早积极使用免疫疗法。

{"title":"Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer","authors":"Li Li, Chunhua Xu, Wei Wang, Qian Zhang","doi":"10.1111/crj.13763","DOIUrl":"10.1111/crj.13763","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to investigate the efficacy and safety of PD-1/PD-L1 inhibitors in treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with advanced NSCLC ≥70 years old who received PD-1/PD-L1 inhibitors in our hospital were retrospectively analyzed. According to age, the patient were stratified as follows: 70–75 years old, 76–80 years old, and >80 years old. Kaplan–Meier method was used for survival analysis, and univariate and multivariate Cox proportional hazards regression models were used to analyze the correlation between different clinical characteristics and survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 58 elderly patients with advanced non-small cell cancer were enrolled in this study. Patients aged 70–75, 76–80, and >80 years old were 32, 19, and 7, respectively. For the all, median OS was 17.0 months, and PFS was 7.0 months. PFS and OS did not differ according to age (<i>P</i> = 0.396, 0.054, respectively). Univariate analysis showed that PS of 0–1, stage III, first-line therapy and irAEs were associated with longer PFS, and PS of 0–1, stage III, and first-line therapy were associated with longer OS. Multivariate analysis showed that patients with stage III had longer PFS. PFS and OS of patients with PS ≥ 2 were significantly shorter than those of patients with PS of 0–1.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In the present real-world retrospective cohort, PD-1/PD-L1 inhibitors are effective and well tolerated in elderly patients with advanced NSCLC. Immunotherapy should be actively used as early as possible in older patients advanced NSCLC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13763","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sublobectomy and lymph node sampling are adequate for patients with invasive lung adenocarcinoma presenting as pure ground glass nodules 对于表现为纯磨碎玻璃结节的浸润性肺腺癌患者，进行肺叶下切除术和淋巴结取样就足够了。

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-07 DOI: 10.1111/crj.13766

Hansheng Wu, Junhan Wu, Xi Chen, Zihua Lan, Qibin Chen, Liangli Hong, Jinhai Yan, Shujie Huang, Jianrong Chen, Xirui Lin, Yong Tang, Haijie Xu, Guibin Qiao

Purpose

In this study, we aimed to investigate the prognosis of invasive lung adenocarcinoma that manifests as pure ground glass nodules (pGGNs) and confirm the effectiveness of sublobectomy and lymph node sampling in patients with pGGN-featured invasive adenocarcinoma (IAC).

Materials and methods

We retrospectively enrolled 139 patients with pGGN-featured IAC, who underwent complete resection in two medical institutions between January 2011 and May 2022. Stratification analysis was conducted to ensure balanced baseline characteristics among the patients. The 5-year overall survival (OS) and disease-free survival (DFS) rates were compared between the groups using Kaplan–Meier survival curves and log-rank test.

Results

The 5-year OS and DFS rates for patients with IAC presenting as pGGNs after surgery were 96.5% and 100%, respectively. No lymph node metastasis or recurrence was observed in any of the enrolled patients. There was no statistically significant difference in the 5-year OS between patients who underwent lobectomy or sublobectomy, along with lymph node resection or sampling.

Conclusion

IAC presented as pGGNs exhibited low-grade malignancy and had a relatively good prognosis. Therefore, these patients may be treated with sublobectomy and lymph node sampling.

目的：本研究旨在探讨表现为纯磨玻璃结节（pGGN）的浸润性肺腺癌的预后，并确认对pGGN特征的浸润性腺癌（IAC）患者进行肺叶下切除术和淋巴结取样的有效性：我们回顾性纳入了2011年1月至2022年5月期间在两家医疗机构接受完整切除术的139例pGGN特征IAC患者。我们进行了分层分析，以确保患者的基线特征均衡。采用卡普兰-米尔生存曲线和对数秩检验比较了两组患者的5年总生存率（OS）和无病生存率（DFS）：结果：术后表现为pGGNs的IAC患者的5年OS和DFS率分别为96.5%和100%。所有入组患者均未发现淋巴结转移或复发。接受肺叶切除术或亚肺叶切除术、淋巴结切除术或取样术的患者的5年生存率在统计学上没有明显差异：结论：表现为pGGNs的IAC恶性程度较低，预后相对较好。因此，这些患者可接受肺叶下切除术和淋巴结取样治疗。

{"title":"Sublobectomy and lymph node sampling are adequate for patients with invasive lung adenocarcinoma presenting as pure ground glass nodules","authors":"Hansheng Wu, Junhan Wu, Xi Chen, Zihua Lan, Qibin Chen, Liangli Hong, Jinhai Yan, Shujie Huang, Jianrong Chen, Xirui Lin, Yong Tang, Haijie Xu, Guibin Qiao","doi":"10.1111/crj.13766","DOIUrl":"10.1111/crj.13766","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>In this study, we aimed to investigate the prognosis of invasive lung adenocarcinoma that manifests as pure ground glass nodules (pGGNs) and confirm the effectiveness of sublobectomy and lymph node sampling in patients with pGGN-featured invasive adenocarcinoma (IAC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>We retrospectively enrolled 139 patients with pGGN-featured IAC, who underwent complete resection in two medical institutions between January 2011 and May 2022. Stratification analysis was conducted to ensure balanced baseline characteristics among the patients. The 5-year overall survival (OS) and disease-free survival (DFS) rates were compared between the groups using Kaplan–Meier survival curves and log-rank test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The 5-year OS and DFS rates for patients with IAC presenting as pGGNs after surgery were 96.5% and 100%, respectively. No lymph node metastasis or recurrence was observed in any of the enrolled patients. There was no statistically significant difference in the 5-year OS between patients who underwent lobectomy or sublobectomy, along with lymph node resection or sampling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>IAC presented as pGGNs exhibited low-grade malignancy and had a relatively good prognosis. Therefore, these patients may be treated with sublobectomy and lymph node sampling.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13766","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GTSE1: A potential prognostic and diagnostic biomarker in various tumors including lung adenocarcinoma GTSE1：包括肺腺癌在内的多种肿瘤的潜在预后和诊断生物标记物。

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-07 DOI: 10.1111/crj.13757

Guanqiang Yan, Guosheng Li, Xiang Gao, Jun Liu, Yue Li, Jingxiao Li, Huafu Zhou

Objective

This research was aimed to comprehensively investigate the expression levels, diagnostic and prognostic implications, and the relationship with immune infiltration of G2 and S phase-expressed-1 (GTSE1) across 33 tumor types, including lung adenocarcinoma (LUAD), through gene expression profiling.

Methods

GTSE1 mRNA expression data together with clinical information were acquired from Xena database of The Cancer Genome Atlas (TCGA), ArrayExpress, and Gene Expression Omnibus (GEO) database for this study. The Wilcoxon rank-sum test was used to detect differences in GTSE1 expression between groups. The ability of GTSE1 to accurately predict cancer status was evaluated by calculating the area under the curve (AUC) value for the receiver operating characteristic curve. Additionally, we investigated the predictive value of GTSE1 in individuals diagnosed with neoplasms using univariate Cox regression analysis as well as Kaplan–Meier curves. Furthermore, the correlation between GTSE1 expression and levels of immune infiltration was assessed by utilizing the Tumor Immune Estimate Resource (TIMER) database to calculate the Spearman rank correlation coefficient. Finally, the pan-cancer analysis findings were validated by examining the association between GTSE1 expression and prognosis among patients with LUAD.

Results

GTSE1 exhibited significantly increased expression levels in a wide range of tumor tissues in contrast with normal tissues (p < 0.05). The expression of GTSE1 in various tumors was associated with clinical features, overall survival, and disease-specific survival (p < 0.05). In immune infiltration analyses, a strong correlation of the level of immune infiltration with the expression of GTSE1 was observed. Furthermore, GTSE1 demonstrated good discriminative and diagnostic value for most tumors. Additional experiments confirmed the relationship between elevated GTSE1 expression and unfavorable prognosis in individuals diagnosed with LUAD. These findings indicated the crucial role of GTSE1 expression level in influencing the development and immune infiltration of different types of tumors.

Conclusions

GTSE1 might be a potential biomarker for the prognosis of pan-cancer. Meanwhile, it represented a promising target for immunotherapy.

研究目的本研究旨在通过基因表达谱分析，全面研究包括肺腺癌（LUAD）在内的33种肿瘤类型中G2和S期表达-1（GTSE1）的表达水平、诊断和预后意义以及与免疫浸润的关系：本研究从癌症基因组图谱（TCGA）的Xena数据库、ArrayExpress和Gene Expression Omnibus（GEO）数据库中获取了GTSE1 mRNA表达数据和临床信息。本研究采用 Wilcoxon 秩和检验检测组间 GTSE1 表达的差异。通过计算接收者操作特征曲线的曲线下面积（AUC）值，评估了GTSE1准确预测癌症状态的能力。此外，我们还利用单变量 Cox 回归分析和 Kaplan-Meier 曲线研究了 GTSE1 对确诊肿瘤患者的预测价值。此外，通过利用肿瘤免疫估算资源（TIMER）数据库计算斯皮尔曼等级相关系数，评估了 GTSE1 表达与免疫浸润水平之间的相关性。最后，通过研究GTSE1表达与LUAD患者预后之间的关系，验证了泛癌症分析结果：结果：与正常组织相比，GTSE1在多种肿瘤组织中的表达水平均明显升高（p 结论：GTSE1可能是一种潜在的肿瘤标志物：GTSE1可能是泛癌症预后的潜在生物标志物。同时，它也是免疫疗法的一个有前途的靶点。

{"title":"GTSE1: A potential prognostic and diagnostic biomarker in various tumors including lung adenocarcinoma","authors":"Guanqiang Yan, Guosheng Li, Xiang Gao, Jun Liu, Yue Li, Jingxiao Li, Huafu Zhou","doi":"10.1111/crj.13757","DOIUrl":"10.1111/crj.13757","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This research was aimed to comprehensively investigate the expression levels, diagnostic and prognostic implications, and the relationship with immune infiltration of G2 and S phase-expressed-1 (<i>GTSE1</i>) across 33 tumor types, including lung adenocarcinoma (LUAD), through gene expression profiling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p><i>GTSE1</i> mRNA expression data together with clinical information were acquired from Xena database of The Cancer Genome Atlas (TCGA), ArrayExpress, and Gene Expression Omnibus (GEO) database for this study. The Wilcoxon rank-sum test was used to detect differences in <i>GTSE1</i> expression between groups. The ability of <i>GTSE1</i> to accurately predict cancer status was evaluated by calculating the area under the curve (AUC) value for the receiver operating characteristic curve. Additionally, we investigated the predictive value of <i>GTSE1</i> in individuals diagnosed with neoplasms using univariate Cox regression analysis as well as Kaplan–Meier curves. Furthermore, the correlation between <i>GTSE1</i> expression and levels of immune infiltration was assessed by utilizing the Tumor Immune Estimate Resource (TIMER) database to calculate the Spearman rank correlation coefficient. Finally, the pan-cancer analysis findings were validated by examining the association between <i>GTSE1</i> expression and prognosis among patients with LUAD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>GTSE1</i> exhibited significantly increased expression levels in a wide range of tumor tissues in contrast with normal tissues (<i>p</i> < 0.05). The expression of <i>GTSE1</i> in various tumors was associated with clinical features, overall survival, and disease-specific survival (<i>p</i> < 0.05). In immune infiltration analyses, a strong correlation of the level of immune infiltration with the expression of <i>GTSE1</i> was observed. Furthermore, <i>GTSE1</i> demonstrated good discriminative and diagnostic value for most tumors. Additional experiments confirmed the relationship between elevated <i>GTSE1</i> expression and unfavorable prognosis in individuals diagnosed with LUAD. These findings indicated the crucial role of <i>GTSE1</i> expression level in influencing the development and immune infiltration of different types of tumors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p><i>GTSE1</i> might be a potential biomarker for the prognosis of pan-cancer. Meanwhile, it represented a promising target for immunotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13757","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantitative analysis of lung lesions using unenhanced chest computed tomography images 利用未增强胸部计算机断层扫描图像对肺部病变进行定量分析。

IF 1.7 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal

Pub Date : 2024-05-07 DOI: 10.1111/crj.13759

Fariba Zarei, Payam Jannatdoust, Siamak Malekpour, Mahshad Razaghi, Sabyasachi Chatterjee, Vani Varadhan Chatterjee, Amirbahador Abbasi, Rezvan Ravanfar Haghighi

Introduction

Chest radiograph and computed tomography (CT) scans can accidentally reveal pulmonary nodules. Malignant and benign pulmonary nodules can be difficult to distinguish without specific imaging features, such as calcification, necrosis, and contrast enhancement. However, these lesions may exhibit different image texture characteristics which cannot be assessed visually. Thus, a computer-assisted quantitative method like histogram analysis (HA) of Hounsfield unit (HU) values can improve diagnostic accuracy, reducing the need for invasive biopsy.

Methods

In this exploratory control study, nonenhanced chest CT images of 20 patients with benign (10) and cancerous (10) lesion were selected retrospectively. The appearances of benign and malignant lesions were very similar in chest CT images, and only pathology report was used to discriminate them. Free hand region of interest (ROI) was inserted inside the lesion for all slices of each lesion. Mean, minimum, maximum, and standard deviations of HU values were recorded and used to make HA.

Results

HA showed that the most malignant lesions have a mean HU value between 30 and 50, a maximum HU less than 150, and a minimum HU between −30 and 20. Lesions outside these ranges were mostly benign.

Conclusion

Quantitative CT analysis may differentiate malignant from benign lesions without specific malignancy patterns on unenhanced chest CT image.

简介胸片和计算机断层扫描（CT）可能会意外发现肺部结节。如果没有特定的成像特征，如钙化、坏死和对比度增强，很难区分恶性和良性肺结节。然而，这些病变可能表现出不同的图像纹理特征，无法通过肉眼进行评估。因此，Hounsfield 单位（HU）值的直方图分析（HA）等计算机辅助定量方法可以提高诊断准确性，减少侵入性活检的需要：在这项探索性对照研究中，我们回顾性地选择了 20 名良性病变（10 人）和癌症（10 人）患者的非增强胸部 CT 图像。良性病变和恶性病变在胸部 CT 图像中的表现非常相似，因此只能通过病理报告来鉴别。每个病灶的所有切片都在病灶内部插入了自由手感兴趣区（ROI）。记录 HU 值的平均值、最小值、最大值和标准偏差，并利用这些值制作 HA：HA显示，大多数恶性病变的平均HU值介于30和50之间，最大HU值小于150，最小HU值介于-30和20之间。结论：结论：定量 CT 分析可在未增强胸部 CT 图像上区分恶性和良性病变，但没有特定的恶性模式。

{"title":"Quantitative analysis of lung lesions using unenhanced chest computed tomography images","authors":"Fariba Zarei, Payam Jannatdoust, Siamak Malekpour, Mahshad Razaghi, Sabyasachi Chatterjee, Vani Varadhan Chatterjee, Amirbahador Abbasi, Rezvan Ravanfar Haghighi","doi":"10.1111/crj.13759","DOIUrl":"10.1111/crj.13759","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Chest radiograph and computed tomography (CT) scans can accidentally reveal pulmonary nodules. Malignant and benign pulmonary nodules can be difficult to distinguish without specific imaging features, such as calcification, necrosis, and contrast enhancement. However, these lesions may exhibit different image texture characteristics which cannot be assessed visually. Thus, a computer-assisted quantitative method like histogram analysis (HA) of Hounsfield unit (HU) values can improve diagnostic accuracy, reducing the need for invasive biopsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this exploratory control study, nonenhanced chest CT images of 20 patients with benign (10) and cancerous (10) lesion were selected retrospectively. The appearances of benign and malignant lesions were very similar in chest CT images, and only pathology report was used to discriminate them. Free hand region of interest (ROI) was inserted inside the lesion for all slices of each lesion. Mean, minimum, maximum, and standard deviations of HU values were recorded and used to make HA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>HA showed that the most malignant lesions have a mean HU value between 30 and 50, a maximum HU less than 150, and a minimum HU between −30 and 20. Lesions outside these ranges were mostly benign.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Quantitative CT analysis may differentiate malignant from benign lesions without specific malignancy patterns on unenhanced chest CT image.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 5","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13759","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0